$13.51−0.07 (−0.52%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Core Scientific (CORZ) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 50% below its peak, net margin −90.5%. Worth your attention in FY25: Share count (+36.3%) and Capex step-up ($729.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼37.5%
319.0
FY21→FY25CAGR −12.5%/yr
Net income ($M)▲79.9%
−288.6
one-off year: see footnoteCAGR —
Free cash flow ($M)▼765.7%
−450.8
capex stepped upCAGR —
Diluted EPS▲81.9%
−0.88
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+36.3%
233.3mn → 318.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$729.0M
▲668% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-90¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 43.9% → 11.9%. Net margin -90.5% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6782, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 592,074.0 | 319,019.0 | 510,672.0 | 502,400.0 | 640,313.0 | 544,483.0 | ▼37.5% | −12.5% |
Cost of revenue | 347,897.0 | 281,121.0 | 403,336.0 | 378,941.0 | 631,913.0 | 305,621.0 | ▼30.3% | −2.1% |
Gross profit | 244,177.0 | 37,898.0 | 121,070.0 | 123,459.0 | 8,400.0 | 238,862.0 | ▼68.7% | −36.9% |
Research & development | — | — | — | — | 26,962.0 | 7,674.0 | — | — |
Selling, general & admin | 174,047.0 | 159,224.0 | 113,691.0 | 108,111.0 | 213,280.0 | 60,486.0 | ▲40.0% | +27.4% |
Total operating expenses | 678,692.0 | 283,487.0 | 249,401.0 | 114,498.0 | 2,117,953.0 | 107,368.0 | ▲13.7% | +27.5% |
Operating incomefeeds ROC rank | −434,015.0 | −245,589.0 | −142,065.0 | 8,961.0 | −2,109,553.0 | 131,494.0 | ▼72.9% | — |
Other income, net | 221,702.0 | −42,444.0 | −1,294,950.0 | −254,765.0 | −53,856.0 | −68,419.0 | — | — |
Pretax income | −212,313.0 | −288,033.0 | −1,437,015.0 | −245,804.0 | −2,163,409.0 | 63,075.0 | ▲80.0% | — |
Income tax | −103,904.0 | 583.0 | 859.0 | 683.0 | −17,091.0 | 15,763.0 | ▼32.1% | −56.1% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −108,409.0 | −288,616.0 | −1,437,874.0 | −246,487.0 | −2,146,318.0 | 47,312.0 | ▲79.9% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −5.54 | −0.88 | −4.87 | −0.65 | −6.30 | 0.20 | ▲81.9% | — |
Diluted shares (mn) | 469.01 | 318.07 | 255.83 | 379.86 | 340.65 | 233.31 | ▲24.3% | +8.1% |
| Margins | ||||||||
Gross margin23rd pct in Financial Services | 41.2% | 11.9% | 23.7% | 24.6% | 1.3% | 43.9% | ▼11.8pp | −32.0pp |
Operating margin | −73.3% | −77.0% | −27.8% | 1.8% | −329.5% | 24.2% | ▼49.2pp | −101.1pp |
Net margin2nd pct in Financial Services | −18.3% | −90.5% | −281.6% | −49.1% | −335.2% | 8.7% | ▲191.1pp | −99.2pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 25% vs a −0% norm for this window, likely a one-time item; see the filing.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Core Scientific's revenue last fiscal year?
Core Scientific reported revenue of $319.0M in fiscal 2025, down 37.5% from fiscal 2024.
What was Core Scientific's net income?
Core Scientific reported net income of −$288.6M in fiscal 2025, a net margin of −90.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

